 Myeloablative Agonists
"Myeloablative Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
| Descriptor ID |
D019653
|
| MeSH Number(s) |
D27.505.696.477.656.750 D27.505.954.248.589
|
| Concept/Terms |
Myeloablative Agonists- Myeloablative Agonists
- Agonists, Myeloablative
- Myeloablative Agonist
- Agonist, Myeloablative
|
Below are MeSH descriptors whose meaning is more general than "Myeloablative Agonists".
Below are MeSH descriptors whose meaning is more specific than "Myeloablative Agonists".
This graph shows the total number of publications written about "Myeloablative Agonists" by people in UAMS Profiles by year, and whether "Myeloablative Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 1 | 1 | 2 | | 2014 | 2 | 1 | 3 | | 2013 | 0 | 1 | 1 | | 2012 | 2 | 0 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2001 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloablative Agonists" by people in Profiles over the past ten years.
-
Mizuno K, Dong M, Fukuda T, Chandra S, Mehta PA, McConnell S, Anaissie EJ, Vinks AA. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clin Pharmacokinet. 2018 05; 57(5):625-636.
-
Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016 08; 30(8):894-900.
-
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.
-
Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2091-2099.
-
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):151-8.
-
Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1949-57.
-
Long G, Waller EK, Gregurek S, Tricot G, Marschner S, Bill J. Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients. J Clin Apher. 2015 Feb; 30(1):1-7.
-
Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol. 2013; 130(3):146-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|